Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/88076
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival |
Author: | Korse, C. Taal, B. Bonfrer, J. Vincent, A. van Velthuysen, M. Baas, P. |
Citation: | Annals of Oncology, 2011; 22(12):2625-2630 |
Publisher: | Oxford University Press (OUP) |
Issue Date: | 2011 |
ISSN: | 0923-7534 1569-8041 |
Statement of Responsibility: | C. M. Korse, B. G. Taal, J. M. G. Bonfrer, A. Vincent, M. L. van Velthuysen and P. Baas |
Abstract: | Background: Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small-cell lung cancer. In well-differentiated neuroendocrine tumours (WDNETs), this study investigates the association between proGRP and tumour characteristics and the prognostic value of proGRP levels compared with chromogranin A (CgA) levels. Patients and methods: Serum samples were obtained in 282 patients with WDNET. The receiver operating characteristic (ROC) curve technique was used to assess specificity and sensitivity in the identification of a primary tumour location. Cox proportional hazards models and Kaplan–Meier curves were constructed to determine the association of patients’ characteristics and tumour markers with survival. Results: For proGRP, the ROC curve indicated a cut-off level of 90 ng/l (approximately twice the upper reference value), with a specificity of 99% and a sensitivity of 43% in distinguishing primary pulmonary tumours from other sites. In the multivariate Cox model, both proGRP and CgA were strongly associated with survival (P < 0.0001 for both variables). Conclusions: A high-risk proGRP level (more than twice the upper reference value) in patients with WDNETs is a strong indication for a primary tumour in the lung. Besides CgA, proGRP is a complementary tumour marker for prognosis and treatment monitoring in patients with neuroendocrine tumour. |
Keywords: | chromogranin A; diagnosis; progastrin-releasing peptide; prognosis; neuroendocrine tumours; survival analysis |
Rights: | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com |
DOI: | 10.1093/annonc/mdr007 |
Published version: | http://dx.doi.org/10.1093/annonc/mdr007 |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.